Abstract Pancreatic cancer continues to have a grim prognosis with 5-year survival rates at less than 5 %.
Introduction
Pancreatic cancer is among the most lethal malignancies, with approximately 45,220 newly diagnosed patients in 2013 alone [1] . Though margin-negative resection is currently the only potentially curative therapy for pancreatic cancer [2] [3] [4] [5] , survival rates for patients with early stage resectable disease are poor with only 22 % of patients surviving beyond 5 years [6] despite modern multimodality treatment approaches due to aggressive tumor biology and likely undetected metastatic disease at the time of presentation. Furthermore, most patients will present with advanced unresectable disease at initial presentation [7, 8] for which 5-year survival rates are dismal at less than 2 % [6] .
Accurate differentiation of benign from malignant disease and correct assessment of disease stage is thus vital to determine optimal treatment approaches [9, 10] . Patients with no evidence of metastatic disease or involvement of the tumor to major blood vessels are candidates for resection. Proper staging therefore distinguishes patients who will benefit from surgery with curative intent from those with more advanced stage disease. Treatment options for locally advanced disease include chemotherapy with or without chemoradiation in efforts to increase the chance for a margin-negative resection. Metastatic pancreatic cancer is managed by systemic chemotherapy alone with palliative radiation administered only in rare cases for symptom control. Thus, reliable techniques for staging of pancreatic cancer are imperative given the critical treatment decisions that follow the initial workup.
Currently, thin-slice (1-3 mm), contrast-enhanced, dualphased multidetector computed tomography (MDCT) with three-dimensional (3-D) reconstruction is the recommended imaging modality for the diagnosis and staging of pancreatic cancer [11] due to its ability to detect smaller tumors with greater sensitivity and to provide greater anatomic detail in the relationship of a suspected mass to local structures [12] especially vasculature [13] . Various other imaging techniques including ultrasonography (US), magnetic resonance imaging (MRI), magnetic resonance cholangiopancreatography (MRCP), and endoscopic ultrasonography (EUS) have previously been employed. Diagnostic accuracy of conventional abdominal US is much lower than that of CT [14] , and though sensitivity and specificity increase with the use of contrast-enhanced Doppler US [15] , operator variability and abdominal gas limit its reliability [9] . MRI and MRCP are also potential tools in the diagnosis of pancreatic cancer, but neither offers a clear advantage in distinguishing benign from malignant disease or assessing disease stage in comparison to CT [11] . EUS may be superior to CT and MRI at identifying small tumors [16, 17] ; however, it is poor at detecting distant spread and again is limited by operator skill and experience [9, 16] .
Positron emission tomography (PET) uses a positronemitting radiopharmaceutical that creates images based on their concentration in a particular tissue. Fluorine-18 labeled fluorodeoxyglucose ( 18 F-FDG), a glucose analog that therefore accumulates in metabolically active cells, is currently the most common tracer used in oncological PET imaging. Given the increased glucose metabolism of cancer cells, 18 F-FDG readily accumulates in malignant pancreatic cancer cells and appears hypermetabolic when imaged using a PET scanner. In contrast, normal pancreas has a relatively low glucose utilization rate with poor accumulation of tracer in the normal pancreas and very weak avidity on 18 F-FDG PET imaging [18] .
Functional imaging offers a theoretical advantage over CT and MRI in the ability to differentiate malignant from benign disease and to detect small lesions, as signal intensity relates to high metabolic activity and uptake of the radiotracer rather than size and tissue structure. Recently, 18 F-FDG positron emission tomography ( 18 F-FDG-PET) has been shown to be useful in the diagnosis, staging, treatment planning, and monitoring of patients with pancreatic cancer. Here we review the role of 18 F-FDG-PET and 18 F-FDG-PET/CT in the initial evaluation and management of pancreatic cancer patients.
Diagnosis
Currently contrast-enhanced, dual-phased MDCT is the standard imaging modality for the initial staging of potential pancreatic cancer given its widespread availability and speed of acquisition [19] . Several studies have demonstrated the superiority of 18 F-FDG-PET over contrast-enhanced CT alone for the diagnosis of suspected pancreatic cancer (Table 1) . A meta-analysis by Orlando and colleagues [20] of 17 studies, each with at least 13 patients who received both 18 F-FDG-PET and CT, analyzed the sensitivity and specificity of the addition of 18 F-FDG-PET as an adjunct to CT compared to CT alone among 290 individuals with pancreatic cancer. The authors report that CT alone was 81 % sensitive and 66 % specific in the diagnosis of pancreatic malignancy. Addition of 18 F-FDG-PET following a positive CT detecting a pancreatic mass dramatically increased the specificity of preoperative imaging to 92 %, though sensitivity did not significantly change at 68 %. When 18 F-FDG-PET followed a negative CT in which a pancreatic mass was not detected, sensitivity and specificity were 73 and 86 %, respectively, supporting the unique consideration of 18 F-FDG-PET when CT is negative and clinical suspicion of a malignancy is high. Overall, this study suggests an added benefit of 18 F-FDG-PET following CT in the diagnosis of pancreatic cancer; however, more prospective studies and cost-effective analyses are needed.
Another more recent meta-analysis by Tang and colleagues [21] F-FDG uptake due to competitive inhibition limiting the detection of a pancreatic lesion [22] . Second, lesions less than 1 cm in diameter are difficult to detect given the low resolution of the PET modality [23] .
Currently, 18 F-FDG-PET is most commonly used in the evaluation of challenging diagnostic cases [19] . Discriminating pancreatic cancer from benign mass-forming lesions such as pancreatitis and cystic pancreatic neoplasms can be difficult based on the fact that only the structural appearance of the pancreas is captured by CT. Given the high metabolic activity of cancer cells, 18 F-FDG-PET may be useful in the differentiation of malignant and benign pancreatic lesions.
Distinguishing between pancreatic cancer and massforming pancreatitis can be challenging based on the similar appearance of the two pathologies on MRI or CT often leading to indeterminate results [24, 25] . Mass-forming pancreatitis occurs when chronic pancreatitis affects only a portion of the pancreas resulting in a mass-like appearance that is challenging to distinguish from a malignancy. Additionally, chronic pancreatitis is a common finding in patients with suspected pancreatic cancer, as it is a risk factor for the development of a pancreatic malignancy [26] . 18 F-FDG-PET could help to differentiate these two diagnoses (Fig. 1) . In a study of 102 patients, 93 patients had confirmed ductal adenocarcinoma and 9 had chronic mass-forming pancreatitis. The mean maximum voxel standardized uptake value (SUVmax) of the pancreatic cancer lesion was significantly higher than that of chronic pancreatitis (5.1±2.1 versus 3.2± 1.8, P <0.05). Based on the elevated metabolic activity of pancreatic cancer, 18 F-FDG-PET demonstrated both greater sensitivity and specificity at 96.8 and 77.5 % for accurate diagnosis compared to CT at 79.6 and 44.4 % [26] . Still, distinguishing pancreatic cancer from pancreatitis, particularly autoimmune pancreatitis, will continue to be a challenge based on 18 F-FDG-PET alone. Approximately 10 % of patients with chronic pancreatitis [27] and as high as 100 % of those with autoimmune pancreatitis [28] have been noted to have 18 F-FDG uptake in the pancreas. Further understanding of the uptake intensity, pattern, and associated findings (such as 18 F-FDG in the salivary glands seen in autoimmune pancreatitis) [29] may help improve the utility of 18 F-FDG-PET in distinguishing pancreatitis from pancreatic cancer.
Preoperative evaluation of the cystic pancreatic neoplasm is another unique scenario where distinction between benign and malignant disease is particularly challenging. Cystic pancreatic neoplasms are increasingly common incidental findings with the more frequent use of US and abdominal imaging [30] . Accurate diagnosis and management could prevent many unnecessary pancreatic resections for benign disease. A particular type of cystic neoplasm called intraductal papillary mucinous neoplasm (IPMN) has the potential to produce an adenoma, carcinoma "in situ," or invasive carcinoma and must be followed closely if not resected. Given the difficulty in obtaining an accurate diagnosis for malignant cases of IPMN, many patients currently undergo unnecessary resections only to identify a benign lesion. MRCP is currently the gold standard for diagnosing malignant IPMNs [22] and CT is commonly used as an adjunct in the initial evaluation process. The largest study assessing the reliability 18 F-FDG-PET in this clinical scenario was by Sperti et al. [31] who demonstrated in their cohort of 64 patients with suspected IPMNs that 18 F-FDG-PET had a greater sensitivity (92 versus 58 %), specificity (97 versus 82 %), and accuracy (95 versus 72 %) than conventional imaging. Another study by Tomimaru et al. [32] reported on 29 patients who underwent CT, 18 F-FDG-PET, and surgery for IPMNs, followed by histopathological examination. They found that the SUVmax F-FDG-PET correlated with the histopathological types of IPMN (benign adenoma, carcinoma in situ, or invasive carcinoma). Specificity, sensitivity, and accuracy were best for an SUVmax of 2.5 and that the combined findings of a mural nodule on CT and an SUVmax of 2.5 were most indicative of a malignant IPMN. Other studies, however, fail to report such a high sensitivity in detecting malignancy within cystic lesions [33, 34] . Saito et al. [35] evaluated the usefulness of dual-phase 18 F-FDG-PET/CT with imaging taken at 60 and 120 min after injection of 18 F-FDG. With a combination of SUVmax cutoffs and an index for retention of 18 F-FDG activity in the later scan, the sensitivity and specificity of identifying early malignant IPMNs were 88 and 94 %, respectively. Still, more research is needed to further understand how standard or dual-phase 18 F-FDG-PET/CT compares to MRCP and ultrasound in the management of cystic pancreatic neoplasms.
Staging
Margin-negative resection is currently the only curative option for pancreatic cancer. Thus, accurate staging is imperative to identify patients who are candidates for surgery from those who require aggressive upfront chemotherapy and/or radiation to improve chances of a margi-negative resection [36, 37] or as a therapy for newly identified metastatic disease.
Resectability is determined by both degree of tumor involvement with abdominal vasculature and absence of distant metastatic disease. Standard preoperative evaluation currently involves the following: (1) CT of the chest, abdomen, and pelvis to evaluate distant metastases and local extent of tumor invasion and (2) endoscopic ultrasound to further detect vascular involvement and to obtain a pathologic diagnosis with fine needle or core biopsy [38] . Even with such an extensive preoperative evaluation, up to 30 % of patients have evidence of distant metastases or local invasion precluding them from resection at the time of laparotomy [39] [40] [41] . Improvements in accurate staging using novel imaging techniques may not only result in fewer unnecessary operations but also decrease the delay in initiating aggressive chemotherapy and/or radiation for patients with more advanced stage disease, optimizing the treatment strategy [42] .
Currently, primary tumor and regional lymph node staging of pancreatic cancer by 18 F-FDG-PET is not indicated for all patients owing to the poor spatial resolution offered by PET and the proximity of peripancreatic lymph nodes to the primary tumor [43, 44] . Alone, 18 F-FDG-PET is not useful in evaluating resectability, largely due to the low spatial resolution of the PET technique. Information regarding degree of vessel and local organ involvement needed to determine resectability is difficult to obtain without contrast-enhanced CT, and the intense radiotracer uptake by cancer cells further obscures the subtle evaluation of local extension and nodal involvement [22, 45] . Moreover, the low spatial resolution is a significant limitation in identifying metastatic disease as 18 F-FDG-PET detects only~50 % of hepatic lesions less than 1 cm [46] .
To take advantage of the information provided by 18 F-FDG-PET, it is possible to fuse PET imaging with a CT and/ or MRI to present functional data within a backdrop of improved anatomic detail. Fusion, however, can be complicated by issues of data transfer, different locations of imaging acquisition, weight loss, and altered alignment that create challenges in interpreting the location of malignancies-particularly in the abdomen where anatomy varies in uptake patterns, size, locations, and orientations at different time points [47, 48] . Acquisition of consecutive 18 F-FDG-PET and CT ( 18 F-FDG-PET/CT) by the same scanner can overcome these limitations and dramatically enhances the usefulness of PET in this clinical scenario [49] . Additionally, 18 F-FDG-PET/CT utilizes whole body imaging, capturing the most common sites of pancreatic metastatic disease (liver, lungs, and bone marrow) [44] .
When combined with a non-contrast CT, several studies demonstrate improved ability of 18 F-FDG-PET/CT, as compared to contrast-enhanced CT alone, in the staging of pancreatic cancer due to superior detection of distant metastatic disease (Fig. 2) . In a series of 16 patients with histologically proven distant metastases reported by Heinrich and colleagues [10] , 18 F-FDG-PET/CT detected metastatic disease in 13 (81 %) patients compared to only 9 (56 %) detected by CT. Consequently, sensitivity and specificity of 18 F-FDG-PET/CT was 81 and 100 % compared to 56 and 95 % respectively for CT. Of the 37 patients deemed resectable by standard staging with contrast-enhanced CT, detection of metastatic disease using 18 F-FDG-PET/CT altered the management in six patients (16 %) by preventing unnecessary surgical exploration. Similarly, Bang et al. [26] reported 18 F-FDG-PET/CT altered the resectability status and, therefore, management in 22 % of patients in their study.
Together, these studies demonstrate that optimal patient selection can be improved by the addition of 18 F-FDG-PET/ CT to standard preoperative imaging.
Building on the tool of 18 F-FDG-PET/CT, Strobel and colleagues [50] showed the feasibility and accuracy of combining 18 F-FDG-PET and contrast-enhanced CT in the investigation of 50 patients with pancreatic cancer to provide what they coined as a "1-stop-shop" for assessing resectability. Of 11 patients with liver metastases in their study, unenhanced 18 F-FDG-PET/CT accurately identified only five cases (sensitivity 46 % and specificity 100 %) compared to enhanced 18 F-FDG-PET/CT, which detected nine cases (sensitivity 82 % and specificity 97 %). In one patient, enhanced In summary, addition of 18 F-FDG-PET to the standard workup of patients with pancreatic cancer appears to improve accuracy in the staging process and subsequently leads to changes in management. Inclusion of contrast enhancement to 18 F-FDG-PET/CT further improves identification of distant metastases (especially the liver) that would otherwise not be discerned through standard imaging or unenhanced 18 F-FDG-PET/CT. Further research is needed to validate these preliminary results and to better understand the impact of 18 F-FDG-PET/CT on patient management, clinical outcomes, and treatment costs.
Radiation treatment
Advances in modern radiation treatment delivery have enabled increasing precision in the deposition of radiation dose to pancreatic tumors while still sparing surrounding normal organs [51] . For radiation treatment of pancreatic cancer, treatment planning has traditionally been targeted to regions of apparent tumor involvement on CT and peripancreatic lymph nodes at risk. Significant intraobserver variability in the interpretation of CT scans has been reported for many disease sites [52] [53] [54] given the difficulty in determining the tumor boundary (microscopic expansion). This raises questions for appropriate targeting of radiation therapy and whether functional imaging can be used to better define the radiation planning treatment volume (PTV). Figure 3 illustrates the incorporation of tumor which is apparent on CT and 18 F-FDG-PET in construction of a modern radiation treatment plan.
The use of molecular 18 F-FDG-PET/CT imaging to generate radiotherapeutic plans has been highly studied in the lung, head and neck, and brain tumors, with data being continuously accumulated for its application in pancreatic and other forms of cancer [48, 51, 55] . In pancreatic cancer, the benefit of PET-based gross tumor volume (PET-GTV) delineation for radiotherapy planning might be most pronounced in differentiating pancreatic tumor from the normal duodenum and small bowel, where CT-based gross tumor volume (CT-GTV) may be overestimated in the tumor region and may lead to a greater incidence of treatment-related toxicity [51] . Fused 18 F-FDG-PET/CT has been hypothesized to be more accurate in GTV delineation in comparison to CT alone by reducing geographic misses and subsequent reduction of treatment failure [55] . Definitive conclusions regarding the prognostic significance or advantage of PET-GTV versus CT-GTV delineation in radiotherapy planning of pancreatic cancer is limited because of breathing motion, organ deformation, and tumor heterogeneity from patient to patient; however, the field is continuously evolving and these major challenges are being addressed.
Treatment response and prognosis
With the grim survival rates and relatively treatment-resistant quality of pancreatic cancer, early assessment of treatment response can be particularly useful in guiding the therapeutic approach and patient counseling. Computed tomography is restricted to evaluating the morphology of the pathology. Additionally, it is difficult to assess the response with CT following radiation therapy due to fibrosis and necrosis in the treated area [19] . Response to treatment by CT is generally evaluated based on Response Evaluation Criteria for Solid Tumors (RECIST) [56, 57] , categorizing disease into complete response, partial response, stable disease, and progressive disease based on tumor dimensions. Functional imaging, however, can more reliably assess the viability of the cancer cells following treatment (Fig. 4) . As such, 18 F-FDG- [58] demonstrated that 18 F-FDG-PET response following one cycle of chemotherapy was associated with improved median overall survival in patients with advanced pancreatic cancer. This association was not seen in patients demonstrating a RECIST response. 18 F-FDG-PET response correlated with time to progression in patients with locally advanced pancreatic cancer in a study by Bang et al. [26] . Although no patients had apparent RECIST response, those exhibiting a >50 % decrease in uptake on 18F-FDG-PET before and after neoadjuvant chemoradiation had improved time to progression than non-responders (300 versus 233 days, P <0.05). In another study, Choi et al. [59] found that patients with ≥50 % decrease in SUV following neoadjuvant chemoradiation underwent successful resection while resection was uncommon in non-responders.
18 F-FDG-PET may also provide early insight into the pathologic response due to treatment. Kittaki et al. [60] reported in a study of 40 patients with resectable pancreatic cancer that patients with a higher SUVmax (≥4.7) and higher SUV decline had a better pathologic response to preoperative gemcitabine-based chemoradiation. Again, RECIST failed to show associations with pathologic response. In another study by Rose et al. [61] , metabolic response was also found to correlate with pathologic scores of tumor response to treatment following neoadjuvant chemoradiation. In summary, preliminary studies suggest that 18 F-FDG-PET is superior to CT in assessing response to treatment in pancreatic cancer, particularly when necrosis and fibrosis following radiation therapy complicates interpretation of CT imaging.
Future directions
The technology and technique behind 18 F-FDG-PET/CT is continuously evolving, and researchers are discovering how to optimize the use of multimodality imaging in cancer care. While 18 F-FDG-PET/CT is increasingly being used in the management of pancreatic adenocarcinoma, several issues will need to be circumvented. For example, the traditional low-dose CT portion of the 18 F-FDG-PET/CT is used for attenuation correction, not diagnosis [22] . Contrast-enhanced 18 F-FDG-PET/CT can provide a greater morphological detail, and restricting intravenous contrast to the abdominal and pelvic portion of the CT can limit radiation exposure of this imaging study [50] . Preliminary data demonstrates the superiority of contrast-enhanced 18 F-FDG-PET/CT over enhanced CT alone [50] . Further research on utility and cost may clarify the role of contrast-enhanced 18 F-FDG-PET/CT for both accurate anatomic localization of primary disease and metabolic evaluation of distant spread.
The second issue with 18 F-FDG-PET/CT arises in the broad differential diagnosis of a PET-avid pancreatic lesion. While 18 F-FDG-PET/CT can reliably distinguish malignant tissue from some benign pancreatic diseases, autoimmune chronic pancreatitis, sclerosing mesenteritis, or other inflammatory conditions can demonstrate considerable 18 F-FDG-uptake (Fig. 5) . Modifying 18 F-FDG-PET/CT acquisition through a delayed technique in which the image is taken after more than 60 min of uptake time may improve the sensitivity and specificity in distinguishing pancreatic cancer from these other benign diseases. Studies have demonstrated that this technique may aid in both discriminating between malignancy and other 18 F-PET-avid lesions and detecting a greater percentage of local and distant lesions [62, 63] .
Preliminary data evaluating the role of 18 F-FDG-PET/CT in assessing response to treatment and predicting improved clinical and pathological outcomes is promising; however, interpretation should be made with caution. A focus on the standard methods of interpreting and reporting radiotracer uptake and response should be maintained to yield clinically useful and reproducible results. Wahl and colleagues [64] have published a framework for reproducible quantified analysis of 18 F-FDG-PET images entitled "PET Response Criteria in Solid Tumors (PERCIST 1.0) modeled after RECIST [56, 57] used for evaluating solid tumor response on CT imaging. They provide precise and rational parameters for measuring metabolic tumor activity and quantifying response in a way that is consistent from patient to patient. Continued efforts to identify a standard definition for parameters quantifying radiotracer uptake and metabolic [65, 66] . Other tracers, such as carbon-11-labeled acetate ( 11 C-acetate), have been studied in the mouse model in an attempt to increase the ability of PET/CT to detect pancreatic cancer [67] . Hyperglycemia in pancreatic cancer patients tends to significantly reduce 18 F-FDG uptake, leading to a significant number of false-negative readings [22] . 11 Cacetate has been shown to be more sensitive than FDG in the detection of cancerous pancreatic lesions, especially during the early stage of disease [67] . In another mouse model, a novel PET/CT tracer was developed to measure tissue factor (TF) expression. The authors reported persistent and specific uptake of (67)Cu-NOTA-ALT-836 in pancreatic cancer cells [68] . Two more non-glucose analog radiotracers have been developed to increase accuracy of early detection of pancreatic adenocarcinoma. Early investigations of these lactose-binding proteins, ethyl-β-D-galactopyranosyl-(1,4′)-2′-deoxy-2′-[ [69, 70] .
Lastly, different combinations of multimodality imaging have been proposed, namely, fused 18 F-FDG-PET and MRI scanning. Tatsumi et al. [71] reported 18 F-FDG-PET/MRI, especially using T1-w-MRI, to be superior to 18 F-FDG-PET/ CT in localizing pancreatic lesions, with better mapping and fusion image quality. While the study obtained the PET and MRI studies from different scanners, work is currently being conducted on designing and testing integrated PET/MRI scanners with ability to simultaneously acquire PET and MRI images, thereby increasing the accuracy of the coregistration process.
Conclusions
While these preliminary studies show promising results, much more research is warranted before the use of non-FDG tracers and fused PET/MRI in clinical practice. However, as research on functional imaging of pancreatic adenocarcinoma is less abundant than other cancer types, patients with pancreatic cancer are continuously encouraged to take part in clinical trials that could ultimately improve their treatment and prognosis.
